查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018620

基于NGS的RNA定序市场：按产品、技术、应用和最终用户划分－2026-2032年全球市场预测

NGS-Based RNA-Sequencing Market by Product, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基于 NGS 的 RNA 定序市值将达到 31.7 亿美元，到 2026 年将成长到 37.7 亿美元，到 2032 年将达到 112 亿美元，年复合成长率为 19.74%。

主要市场统计数据
基准年 2025 31.7亿美元
预计年份：2026年 37.7亿美元
预测年份 2032 112亿美元
复合年增长率 (%) 19.74%

全面介绍基于 NGS 的 RNA定序的创新及其对转化研究、临床流程和生物资讯整合的影响。

基于次世代定序（NGS）的RNA定序已从最初的科研兴趣发展成为支持发现、诊断和治疗方法研发的基础平台。该技术能够以高灵敏度和高分辨率对转录组进行定量分析，并已应用于从生物标记鑑定到阐明细胞异质性等多种领域。随着研究机构采用更复杂的工作流程和计算流程，RNA定序在从早期研究到临床应用的决策过程中发挥日益关键的作用。

对改变 RNA定序实践和转化研究成果的关键技术、操作和协作变革进行详细分析。

RNA定序的现况正受到多种因素的共同影响，而不仅仅是处理能力的提升。首先，从批量分析到单细胞和空间转录组学的转变，揭示了细胞异质性和组织结构，从根本上改变了我们对生物学结果的解释。这种转变需要新的样品製备方案、更精细的品管以及稀疏数据分析方法。因此，研究团队现在在设计实验时，会着眼于细胞层面的分辨率，这影响到从试剂选择到下游计算资源的各个层面。

我们将密切关注 2025 年关税变化将如何影响整体RNA定序业务的供应链韧性、筹资策略和供应商关係。

影响关税的政策变化会对整个生命科学供应链产生连锁反应，进而影响成本、供应商关係和筹资策略。在试剂、仪器和专用耗材的跨国采购环境中，关税上涨会推高商品总成本，促使企业重新评估筹资策略。许多实验室面临采购週期延长和库存管理日益受到重视的问题。采购团队正在优先考虑延长前置作业时间，并寻找替代供应商以减少供应中断。

综合細項分析，解释应用程式、产品、最终用户和技术如何组合形成客製化的工作流程、功能需求和策略重点。

从应用角度分析部署情况，可以清楚揭示影响需求和投资的用例。生物标记发现着重于早期识别和检验，因此需要高通量可重复性和严格的检验流程来支援下游临床应用。药物发现和开发则受到不同的限制。药物动力学研究优先考虑定量准确性，标靶辨识需要广泛的转录组覆盖，而毒理学研究则优先考虑对罕见或低表达转录物的敏感性。基因表现谱分析包括适用于群体层级讯号的批量分析，以及用于揭示细胞和微环境细微差异的单细胞和空间分析。个人化医疗需要整合伴随诊断和治疗监测，以提供符合监管标准的、可操作的、针对特定患者的见解和证据。

对影响世界各地 RNA定序技术采用的能力生态系统、监管环境和伙伴关係模式进行必要的区域分析。

区域差异导致了独特的技术应用模式和战略重点。在美洲，由科研密集型机构和生物技术公司组成的紧密网络支撑着一个充满活力的技术应用生态系统，促进了转化研究合作和官民合作关係。这种环境有利于新型定序方法的快速应用，并推动仪器供应商与早期使用者之间的密切合作，而法律规范和报销途径则持续影响临床应用的进程。

从企业层面提供可操作的观点，探讨竞争差异化、伙伴关係策略以及推动采用和长期客户参与的能力投资。

RNA定序生态系统中的主要企业透过整合独特的化学技术、仪器工程、软体生态系统以及降低准入门槛的服务来脱颖而出。那些将强大的硬体、可扩充性的云端分析能力和卓越的客户支援相结合的公司，正在为高通量研究和临床客户创造持续的竞争优势。此外，提供整合耗材和检验的工作流程的供应商能够降低变异性并缩短结果获取时间，这在临床诊断和受监管的研究中尤其重要。

为领导者提供关键建议，以实现快速部署和风险缓解，包括技术选择协调、工作流程标准化以及加强供应链和分析策略。

领导者首先应将研究目标与技术选择相匹配，并确保所选定序方法（批量测序、单细胞测序、长读长测序或空间定序）能够直接解决关键的生物学挑战。这种匹配可以减少下游流程中的重复工作，并优化资源分配。其次，各机构应投资于标准化的样本工作流程和品管查核点，以确保不同地点和研究的结果可重复。这有助于提高人们对探索性研究和临床结果的信心。

清楚地解释用于得出见解的跨学科调查方法和检验框架，确保透明度、可重复性和可操作性。

本分析整合了来自对领域专家的访谈、对已发表方案的技术评估以及对同行评审文献的系统性回顾，以全面检验相关趋势和实际应用。我们从研究所所长、检体采购经理和生物资讯学专家处收集了主要的定性信息，以了解实际操作情况和检验重点。技术评估包括对工作流程要素（例如样品製备方法、读长的影响和检体品质阈值）进行基准测试，旨在为选择合适的技术提供依据。

透过将技术创新、营运要求和策略路径整合到简洁的结论中，我们可以创建可重复且具有临床意义的 RNA定序程序。

总之，RNA定序正处于技术创新和营运转型的十字路口。单细胞、长读长和空间转录组学的进步正在拓展可解决的生物学难题范围，而不断变化的价值链趋势和监管环境则要求采购和专案管理采用新的方法。那些能够将技术选择与科学目标紧密结合、投资于可重复的工作流程并建立灵活伙伴关係的机构，将能够最大限度地发挥这些进步的价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 基于NGS的RNA定序市场：依产品分类

  • 消耗品
    • 酵素
    • 试剂和试剂盒
  • 装置
    • 数据分析平台
    • 样品製备装置
    • 序列器
  • 服务
    • 生物资讯分析服务
    • 专案管理服务
    • 样品製备服务

第九章：基于NGS的RNA定序市场：依技术分类

  • 大量定序
  • 长读长定序
  • 单细胞定序
  • 空间转录组学

第十章：基于NGS的RNA定序市场：依应用划分

  • 生物标记发现
    • 早期生物标誌物的鑑定
    • 检验
  • 药物发现与开发
    • 药物动力学研究
    • 目标识别
    • 毒性测试
  • 基因表现分析
    • 批量分析
    • 单细胞分析
    • 空间剖面分析
  • 个人化医疗
    • 伴随诊断
    • 治疗监测

第十一章 基于NGS的RNA定序市场：依最终用户划分

  • 学术机构及政府机构
    • 研究机构
    • 大学
  • 临床诊断检查室
    • 医院检查室
    • 独立检测实验室
  • 合约研究机构
  • 製药和生物技术公司
    • 生技公司
    • 製药公司

第十二章：基于NGS的RNA定序市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：基于NGS的RNA定序市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 以NGS为基础的RNA定序市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基于NGS的RNA定序市场

第十六章：中国基于NGS的RNA定序市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies
  • Astrea Bioseparations Ltd.
  • Azenta Life Sciences
  • Becton, Dickinson and Company
  • BGI Group
  • Brooks Automation Inc
  • DNASTAR, Inc.
  • Eurofins Scientific
  • F. Hoffmann-la Roche AG
  • Genewiz by Brooks Automation, Inc.
  • Genomnia srl
  • Hamilton Company
  • Illumina, Inc.
  • Merck KGaA
  • Microsynth AG
  • Mina INC
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • PerkinElmer, Inc.
  • Precigen, Inc
  • Psomagen Inc.
  • Qiagen NV
  • Seqomics Kft.
  • Takara Bio Inc.
  • Tecan genomics
  • Thermo Fisher Scientific
Product Code: MRR-2214614769D5

The NGS-Based RNA-Sequencing Market was valued at USD 3.17 billion in 2025 and is projected to grow to USD 3.77 billion in 2026, with a CAGR of 19.74%, reaching USD 11.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.17 billion
Estimated Year [2026] USD 3.77 billion
Forecast Year [2032] USD 11.20 billion
CAGR (%) 19.74%

Comprehensive introduction to NGS-based RNA sequencing innovations and their implications for translational research clinical pipelines and bioinformatics integration

Next-generation sequencing (NGS)-based RNA sequencing has progressed from an academic curiosity to a foundational platform that underpins discovery, diagnostics, and therapeutic development. The technique's capacity to quantify transcriptomes with high sensitivity and resolution now supports diverse applications ranging from biomarker identification to the interrogation of cellular heterogeneity. As laboratories adopt more sophisticated workflows and computational pipelines, RNA sequencing increasingly informs decisions across early-stage research and clinical translation.

In addition, innovations in library preparation, read-length optimization, and multi-modal integration have expanded the utility of RNA sequencing in complex biological contexts. These technical advances have been accompanied by shifts in laboratory practices, heightened expectations for reproducible analyses, and new demands for regulatory alignment. Consequently, leaders in academia, diagnostics, and industry must understand not only the technology, but also operational considerations such as sample handling, data governance, and cross-disciplinary collaboration.

This introduction frames the discussion for stakeholders who need to align scientific capabilities with strategic objectives. It highlights why RNA sequencing is now a central asset in translational pipelines, and it outlines the contours of the landscape that follow in subsequent sections.

Detailed analysis of the major technological operational and collaborative shifts that are transforming RNA sequencing practices and translational research outcomes

The landscape of RNA sequencing has been reshaped by several convergent forces that extend beyond raw throughput improvements. First, the move from bulk to single-cell and spatial transcriptomics has fundamentally changed biological interpretation by illuminating cellular heterogeneity and tissue architecture. This transition has demanded new sample preparation protocols, refined quality controls, and analytical methods capable of resolving sparse data. As a result, research teams now design experiments with cellular resolution in mind, which influences everything from reagent selection to downstream computational resources.

Second, long-read sequencing technologies have emerged as a complementary approach, enabling the detection of full-length isoforms and complex transcript structures that short reads can miss. This capability is accelerating our understanding of alternative splicing, fusion transcripts, and transcript isoform regulation, which in turn informs target validation and biomarker refinement. The adoption of long-read approaches also requires reassessment of library construction workflows and data storage approaches because of differing error profiles and data formats.

Third, integration with multi-omics and cloud-enabled bioinformatics platforms is driving collaborative, reproducible analyses across institutions. As workflows become modular and interoperable, teams can combine transcriptomic data with proteomics and epigenomics to generate higher-confidence biological hypotheses. Taken together, these shifts are not merely technical; they alter how organizations prioritize investments, structure collaborations, and translate discovery into clinical application.

Rigorous exploration of how tariff shifts in 2025 could reshape supply chain resilience procurement strategies and vendor relationships across RNA sequencing operations

Policy changes that affect tariffs can ripple through the life sciences supply chain, influencing costs, supplier relationships, and procurement strategies. In contexts where reagents, instruments, and specialized consumables cross borders, higher duties increase the landed cost of goods and create incentives to revisit sourcing strategies. For many laboratories, this results in longer procurement cycles and elevated attention to inventory management, with procurement teams prioritizing longer lead times and alternative suppliers to mitigate supply interruptions.

Moreover, tariffs can accelerate localization and near-shoring efforts as institutions and vendors seek to reduce exposure to cross-border duties and currency volatility. Suppliers may respond by establishing regional manufacturing hubs or by optimizing their product portfolios to reduce the number of tariff-affected components. In parallel, service providers and contract research organizations may adapt by offering bundled, end-to-end solutions that absorb some supply chain risks on behalf of customers, thereby simplifying procurement for research and clinical laboratories.

Consequently, research groups must reassess vendor contractual terms, explore multi-sourcing, and consider the total cost of ownership when selecting instruments and consumables. In addition, strategic purchasing decisions will increasingly weigh supply continuity, regional support, and the flexibility to pivot between reagents or platforms without compromising data comparability. Ultimately, tariff-related pressures are prompting organizations to adopt more resilient supply chain strategies and a greater emphasis on partnership models that balance cost, reliability, and performance.

Integrated segmentation analysis explaining how applications products end users and technologies combine to shape tailored workflows capability needs and strategic priorities

Analyzing adoption through the lens of application reveals distinct use-cases that shape requirements and investments. Biomarker discovery, with its focus on early-stage identification and validation, demands high-throughput reproducibility and rigorous validation pipelines to support downstream clinical translation. Drug discovery and development imposes orthogonal constraints: pharmacokinetic studies emphasize quantitative precision, target identification requires broad transcriptome coverage, and toxicology studies prioritize sensitivity for rare or low-abundance transcripts. Gene expression profiling spans bulk approaches suited to population-level signals as well as single-cell and spatial profiling that reveal cellular and microenvironmental nuances. Personalized medicine requires integration across companion diagnostics and therapeutic monitoring to deliver actionable, patient-specific insights and regulatory-grade evidence.

From a product perspective, consumables such as enzymes, reagents and kits determine assay sensitivity and consistency, while instruments including library preparation platforms, sequencers and data analysis platforms define throughput, read quality, and workflow automation. Services layer adds further value through bioinformatics analysis, project management, and sample preparation expertise that reduce adoption friction and accelerate time-to-insight. These product and service distinctions influence procurement strategies and the division of labor across internal teams and external partners.

End users exhibit varied priorities that influence solution design and support models. Academic and government research entities-comprising research institutes and universities-prioritize methodological flexibility and novel applications, whereas clinical diagnostics laboratories including hospital and independent labs emphasize regulatory compliance, sample traceability, and turnaround times. Contract research organizations operate on delivery-driven models that require scalable workflows and robust quality management, and pharmaceutical and biotechnology companies balance discovery throughput with the rigor needed for preclinical and clinical development.

Technology segmentation underscores that bulk sequencing remains a workhorse for population and cohort studies, long-read sequencing provides unmatched isoform and structural insights, single-cell sequencing resolves cellular heterogeneity, and spatial transcriptomics captures tissue context. Each technology imposes different requirements for experimental design, data processing, and interpretation, and successful programs calibrate their investments to match the specific scientific question while ensuring interoperability where multi-technology strategies are employed.

Essential regional analysis of capability ecosystems regulatory landscapes and partnership models that influence the adoption of RNA sequencing innovations across global territories

Regional differences drive distinct adoption patterns and strategic priorities. In the Americas, research-intensive institutions and a dense network of biotechnology companies support a vibrant ecosystem for technology adoption, translational collaborations, and private-public partnerships. This environment encourages rapid deployment of new sequencing modalities and close engagement between instrument vendors and early adopters, while regulatory frameworks and reimbursement pathways continue to influence clinical translation timelines.

Europe, the Middle East and Africa present a heterogeneous landscape in which regulatory harmonization efforts, cross-border research consortia, and national funding initiatives shape capacity building. Many countries in this region invest strategically in infrastructure to support genomic medicine and translational research, creating opportunities for consortium-driven studies and regional manufacturing or distribution partnerships. Meanwhile, disparate regulatory regimes encourage solutions that emphasize interoperability, data protection, and cross-jurisdictional compliance.

Asia-Pacific demonstrates a strong emphasis on scale, localization, and rapid uptake of innovative workflows, with significant investments in both academic centers and commercial biotech. Regional priorities often include building domestic manufacturing capability, expanding clinical sequencing services, and integrating digital health platforms. Consequently, companies and institutions operating across these regions must tailor their engagement strategies to account for differences in procurement practices, regulatory expectations, and local partnerships that support deployment at scale.

Actionable company-level perspectives on competitive differentiation partnership strategies and capability investments that drive adoption and long-term customer engagement

Leading organizations in the RNA sequencing ecosystem differentiate through a combination of proprietary chemistry, instrument engineering, software ecosystems, and services that lower barriers to adoption. Companies that pair robust hardware with scalable cloud-enabled analysis and strong customer support create durable advantages for high-throughput research and clinical customers. In addition, vendors that offer integrated consumables and validated workflows reduce variability and accelerate time-to-results, which is particularly valuable for clinical diagnostics and regulated studies.

Partnerships between instrument providers, reagent manufacturers, and bioinformatics firms have produced more end-to-end solutions that appeal to organizations seeking turnkey capabilities. Strategic alliances with contract research organizations and academic consortia further extend reach into specialized applications such as spatial transcriptomics and single-cell analytics. Meanwhile, service-focused firms that provide deep bioinformatics expertise and sample handling capabilities help bridge gaps for institutions that lack in-house computational resources.

As competitive dynamics evolve, companies that invest in interoperability, open APIs, and community-driven analysis frameworks are better positioned to capture long-term engagement from research networks. Equally important is the ability to demonstrate real-world utility through peer-reviewed validations and regulatory-compliant studies that verify performance in clinically relevant settings. These company-level strategies are central to shaping adoption, partner selection, and customer retention across the ecosystem.

High-impact recommendations for leaders to align technology selection standardize workflows and strengthen supply chain and analytics strategies for rapid adoption and risk mitigation

Leaders should begin by aligning research objectives with technology selection, ensuring that the chosen sequencing approach-bulk, single-cell, long-read, or spatial-directly addresses the primary biological question. This alignment reduces downstream rework and optimizes resource allocation. Next, organizations should invest in standardized sample workflows and quality-control checkpoints that enable reproducible outcomes across sites and studies, thereby enhancing confidence in both discovery and clinical results.

To mitigate supply chain and procurement risks, institutions should cultivate multi-vendor relationships and explore regional sourcing options that can provide continuity under shifting trade policies. Concurrently, building internal bioinformatics capacity while leveraging external service partners for specialized analyses creates a hybrid model that balances control with scalability. Investing in interoperable data infrastructures and clear data governance policies will facilitate multi-omics integration, collaboration, and compliance with regional regulations.

Finally, industry leaders should prioritize transparent validation studies and regulatory engagement early in the development lifecycle. Demonstrating clinical utility and robustness through rigorous, externally validated studies accelerates stakeholder buy-in and supports downstream adoption. By following these prioritized actions, organizations can extract greater value from RNA sequencing technologies while reducing operational and strategic risk.

Clear explanation of the multidisciplinary research methodology and validation framework used to derive insights ensuring transparency reproducibility and actionable relevance

The analysis synthesizes insights from primary interviews with domain experts, technical evaluation of published protocols, and systemic review of peer-reviewed literature to triangulate trends and practical implications. Primary qualitative inputs were obtained from laboratory directors, procurement leads, and bioinformatics specialists to capture operational realities and validation priorities. Technical assessments included benchmarking of workflow elements such as library preparation methods, read-length implications, and sample quality thresholds to contextualize technology fit for purpose.

Analytical methods emphasize reproducibility and traceability: key assertions were validated against multiple independent sources and methodological limitations were explicitly noted. Comparative assessments focused on capability differentiation rather than quantitative market metrics, and case studies were used to illustrate how technology choices influenced outcomes across discovery and clinical workflows. Where appropriate, regulatory documents and publicly available guidance informed considerations around clinical implementation and compliance.

This methodology aims to provide readers with a transparent basis for the findings and recommendations presented, and it supports informed decision-making by highlighting both technical nuances and practical constraints that affect deployment and adoption of RNA sequencing technologies.

Concise concluding synthesis linking technological innovation operational imperatives and strategic pathways to enable reproducible and clinically relevant RNA sequencing programs

In closing, RNA sequencing stands at the confluence of technological innovation and operational transformation. Advances in single-cell, long-read, and spatial transcriptomics are expanding the scope of biological questions that can be addressed, while evolving supply chain dynamics and regulatory landscapes require new approaches to procurement and program management. Organizations that thoughtfully align technology choices with scientific objectives, invest in reproducible workflows, and build flexible partnerships will be best positioned to capture the value of these advances.

Moving forward, the most successful programs will integrate robust bioinformatics, prioritize cross-disciplinary collaboration, and prepare for regulatory and commercial constraints that influence clinical translation. By adopting resilient supply strategies and investing in validation pathways, stakeholders can accelerate the translation of transcriptomic insights into actionable clinical and research outcomes. This conclusion underscores the need for strategic planning that bridges innovation, practicality, and compliance to enable sustainable impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. NGS-Based RNA-Sequencing Market, by Product

  • 8.1. Consumables
    • 8.1.1. Enzymes
    • 8.1.2. Reagents And Kits
  • 8.2. Instruments
    • 8.2.1. Data Analysis Platforms
    • 8.2.2. Library Prep Instruments
    • 8.2.3. Sequencers
  • 8.3. Services
    • 8.3.1. Bioinformatics Analysis Services
    • 8.3.2. Project Management Services
    • 8.3.3. Sample Preparation Services

9. NGS-Based RNA-Sequencing Market, by Technology

  • 9.1. Bulk Sequencing
  • 9.2. Long-Read Sequencing
  • 9.3. Single-Cell Sequencing
  • 9.4. Spatial Transcriptomics

10. NGS-Based RNA-Sequencing Market, by Application

  • 10.1. Biomarker Discovery
    • 10.1.1. Early-Stage Biomarker Identification
    • 10.1.2. Validation
  • 10.2. Drug Discovery & Development
    • 10.2.1. Pharmacokinetic Studies
    • 10.2.2. Target Identification
    • 10.2.3. Toxicology Studies
  • 10.3. Gene Expression Profiling
    • 10.3.1. Bulk Profiling
    • 10.3.2. Single-Cell Profiling
    • 10.3.3. Spatial Profiling
  • 10.4. Personalized Medicine
    • 10.4.1. Companion Diagnostics
    • 10.4.2. Therapeutic Monitoring

11. NGS-Based RNA-Sequencing Market, by End User

  • 11.1. Academic & Government
    • 11.1.1. Research Institutes
    • 11.1.2. Universities
  • 11.2. Clinical Diagnostics Laboratories
    • 11.2.1. Hospital Laboratories
    • 11.2.2. Independent Laboratories
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical & Biotechnology Companies
    • 11.4.1. Biotechnology Companies
    • 11.4.2. Pharmaceutical Companies

12. NGS-Based RNA-Sequencing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. NGS-Based RNA-Sequencing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. NGS-Based RNA-Sequencing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States NGS-Based RNA-Sequencing Market

16. China NGS-Based RNA-Sequencing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies
  • 17.6. Astrea Bioseparations Ltd.
  • 17.7. Azenta Life Sciences
  • 17.8. Becton, Dickinson and Company
  • 17.9. BGI Group
  • 17.10. Brooks Automation Inc
  • 17.11. DNASTAR, Inc.
  • 17.12. Eurofins Scientific
  • 17.13. F. Hoffmann-la Roche AG
  • 17.14. Genewiz by Brooks Automation, Inc.
  • 17.15. Genomnia srl
  • 17.16. Hamilton Company
  • 17.17. Illumina, Inc.
  • 17.18. Merck KGaA
  • 17.19. Microsynth AG
  • 17.20. Mina INC
  • 17.21. Oxford Nanopore Technologies
  • 17.22. Pacific Biosciences of California, Inc.
  • 17.23. PerkinElmer, Inc.
  • 17.24. PerkinElmer, Inc.
  • 17.25. Precigen, Inc
  • 17.26. Psomagen Inc.
  • 17.27. Qiagen N.V.
  • 17.28. Seqomics Kft.
  • 17.29. Takara Bio Inc.
  • 17.30. Tecan genomics
  • 17.31. Thermo Fisher Scientific

LIST OF FIGURES

  • FIGURE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 270. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 272. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 273. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 279. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 280. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 283. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 284. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION NGS-BASED RNA-SEQUENCIN